B. Riley lowered the firm’s price target on Perspective Therapeutics (CATX) to $9 from $17 and keeps a Buy rating on the shares. After taking another look at the dose-escalation data, B. Riley finds it “puzzling” how VMT-alpha-NET showed such low efficacy at 5 mCi, and uncertainty remains whether Perspective can convince the FDA to allow the 7.5 mCi dose, the analyst tells investors in a research note. If VMT-alpha-NET ends up having a similar efficacy profile as AlphaMedix, Perspective could trade at a 30%-50% enterprise value of OranoMed, B. Riley says.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CATX:
- Perspective Therapeutics price target lowered to $16 from $25 at RBC Capital
- Perspective Therapeutics downgraded to Neutral from Buy at BofA
- Perspective Therapeutics price target lowered to $16 from $22 at Oppenheimer
- Perspective Therapeutics selloff a buying opportunity, says JonesResearch
- Perspective Therapeutics Inc trading resumes
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
